# Organigram Global Inc.: overview OGI · Nasdaq · CIK 1620737 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/ogi.md) · [Financials](/companies/ogi/financials.md) · [Filings](/companies/ogi/filings.md) · [Insiders](/companies/ogi/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2019 (2019-08-31) | FY2020 (2020-08-31) | FY2021 (2021-08-31) | FY2022 (2022-08-31) | FY2024 (2024-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [80.4](/filings/0001062993-20-005949.md) | [86.8](/filings/0001062993-21-011478.md) | [79.2](/filings/0001628280-22-030921.md) | [146](/filings/0001628280-23-041900.md) | [160](/filings/0001628280-24-051826.md) | | Gross margin | % | [60.3%](/filings/0001062993-20-005949.md) | [(65.1%)](/filings/0001062993-21-011478.md) | [(35.9%)](/filings/0001628280-22-030921.md) | [21.7%](/filings/0001628280-23-041900.md) | [29.7%](/filings/0001628280-24-051826.md) | | Operating margin | % | [6.8%](/filings/0001062993-20-005949.md) | [(167.6%)](/filings/0001062993-21-011478.md) | [(116.0%)](/filings/0001628280-22-030921.md) | [(29.6%)](/filings/0001628280-23-041900.md) | [(22.3%)](/filings/0001628280-24-051826.md) | | Net margin | % | [(11.9%)](/filings/0001062993-20-005949.md) | [(156.9%)](/filings/0001062993-21-011478.md) | [(165.1%)](/filings/0001628280-22-030921.md) | [(9.8%)](/filings/0001628280-23-041900.md) | [(28.4%)](/filings/0001628280-24-051826.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001062993-20-005949.md) | [(0.79)](/filings/0001062993-21-011478.md) | [(0.51)](/filings/0001628280-22-030921.md) | [(0.18)](/filings/0001628280-23-041900.md) | [(0.48)](/filings/0001628280-24-051826.md) | | Free cash flow | $m | [(144)](/filings/0001062993-20-005949.md) | [(122)](/filings/0001062993-21-011478.md) | [(40.3)](/filings/0001628280-22-030921.md) | [(85.0)](/filings/0001628280-23-041900.md) | [(0.9)](/filings/0001628280-24-051826.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ogi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Tidal Investments LLC](/funds/1600064.md) | 2026-06-30 | $2.2m | 2,164,878 | | Reduced −3,519 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.5m | 1,444,148 | | Reduced −195,900 | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $905.8k | 888,057 | | Reduced −59,383 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $623.7k | 611,479 | | Added +40,110 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $314.3k | 308,108 | | Reduced −56,076 | | [Baader Bank Aktiengesellschaft](/funds/1542629.md) | 2026-06-30 | $254.5k | 250,000 | | Reduced −12,980 | | [BANK OF MONTREAL /CAN/](/funds/927971.md) | 2026-06-30 | $243.5k | 238,434 | | Added +380 | | [Formidable Asset Management, LLC](/funds/1592613.md) | 2026-06-30 | $214.8k | 160,311 | | Added +3,562 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $212.9k | 208,770 | | Added +176,155 | | [Leonteq Securities AG](/funds/1535950.md) | 2026-06-30 | $180.4k | 124,849 | | Reduced −13,662 | ## Recent filings [All 320 filings](/companies/ogi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 15:32 ET | [6-K](/filings/0001628280-26-065965.md) | Report of a foreign private issuer, period 2026-10-15 | 0001628280-26-065965 | | 2026-09-30 | 19:26 ET | [6-K](/filings/0001628280-26-063957.md) | Report of a foreign private issuer, period 2026-09-30 | 0001628280-26-063957 | | 2026-09-03 | 10:53 ET | [6-K](/filings/0001628280-26-060243.md) | Report of a foreign private issuer, period 2026-09-30 | 0001628280-26-060243 | | 2026-09-01 | 01:02 ET | [6-K](/filings/0001062993-26-004753.md) | Report of a foreign private issuer, period 2026-02-18 | 0001062993-26-004753 | | 2026-08-20 | 17:53 ET | [6-K](/filings/0001628280-26-058209.md) | Report of a foreign private issuer, period 2026-08-20 | 0001628280-26-058209 | | 2026-08-11 | 11:33 ET | [6-K](/filings/0001628280-26-055496.md) | Report of a foreign private issuer, period 2026-06-30 | 0001628280-26-055496 | | 2026-08-04 | 14:00 ET | [6-K](/filings/0001628280-26-052218.md) | Report of a foreign private issuer, period 2026-08-04 | 0001628280-26-052218 | | 2026-07-20 | 20:53 ET | [6-K](/filings/0001628280-26-048830.md) | Report of a foreign private issuer, period 2026-07-20 | 0001628280-26-048830 | | 2026-05-12 | 11:43 ET | [6-K](/filings/0001628280-26-033882.md) | Report of a foreign private issuer, period 2026-03-31 | 0001628280-26-033882 | | 2026-05-06 | 19:28 ET | [6-K](/filings/0001628280-26-031177.md) | Report of a foreign private issuer, period 2026-05-06 | 0001628280-26-031177 | ## Latest annual report [Form 40-F for the fiscal year ended Sep 30, 2025](/filings/0001628280-25-057233.md), filed Dec 16, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1620737 - Tickers: OGI - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: Z4 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.